Federal center hopes to spur drug research

Jan 23, 2011

(AP) -- Federal officials concerned about the slowing pace of new drugs coming out of the pharmaceutical industry have decided to start a billion-dollar government drug development center to help create medicines.

The New York Times reported on its website Saturday about the new effort that comes as many large drug makers, unable to find enough new drugs, are trimming back research.

Promising discoveries in illnesses like and Parkinson's that once would have led to are instead going unexplored because companies are not inclined and do not have the money to undertake the effort.

The paper reports that initial financing of the government's new drug center is relatively small compared with the $45.8 billion that the industry estimates it invested in research in 2009. The cost of bringing a single drug to market can exceed $1 billion, according to some estimates.

The drug industry's research productivity has been declining for 15 years and shows few signs of reversing that trend, said Dr. Francis S. Collins, director of the National Institutes of Health.

The new center, to be called the National Center for Advancing Translational Sciences, will do as much as it needs to so that it can attract drug company investment.

Explore further: Evidence lacking for long-term opioid use in low back pain

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Debate sparked over U.S. drug spending

Oct 23, 2006

A doctor at New York's Weill Cornell Medical College has defended U.S. drug spending, which accounts for 42 percent of drug sale money worldwide.

Business of drug development on verge of great change

Apr 01, 2008

Significant changes to drug discovery and the pharmaceutical industry currently underway will increase in the next five to 10 years, according to a top researcher at the National Institutes of Health (NIH) who is helping ...

Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

Trials find no benefits of Zetia

Jan 15, 2008

The U.S. makers of the cholesterol-lowering drug Zetia say a clinical trial failed to identify any medical benefits of the medication.

Recommended for you

Pyridoxine-doxylamine drug safety data lacking

Apr 16, 2014

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

FDA approves new type 2 diabetes drug

Apr 15, 2014

(HealthDay)—Millions of Americans with type 2 diabetes have a new treatment option with the U.S. Food and Drug Administration's approval Tuesday of a once-weekly injectable drug, Tanzeum.

User comments : 0

More news stories

Bionic ankle 'emulates nature'

These days, Hugh Herr, an associate professor of media arts and sciences at MIT, gets about 100 emails daily from people across the world interested in his bionic limbs.

Smoking's toll on mentally ill analyzed

Those in the United States with a mental illness diagnosis are much more likely to smoke cigarettes and smoke more heavily, and are less likely to quit smoking than those without mental illness, regardless ...

Net neutrality balancing act

Researchers in Italy, writing in the International Journal of Technology, Policy and Management have demonstrated that net neutrality benefits content creator and consumers without compromising provider innovation nor pr ...